文献速递血栓与止血浆细胞疾病

IMPEDE VTE评分:多发性骨髓瘤静脉血栓栓塞风险预测模型的开发与验证

Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score.
PubMed 文献 · Am J Hematol · 2019-08-19

研究利用退伍军人事务部中央癌症登记处4446例新诊断多发性骨髓瘤化疗患者开发VTE风险评分,并在SEER-Medicare数据库4256例中外部验证。IMPEDE VTE评分在开发队列c-statistic为0.66,验证队列为0.64,优于IMWG/NCCN指南的0.55。

要点

  • IMPEDE VTE评分在开发队列c-statistic=0.66,外部验证队列c-statistic=0.64。
  • IMWG/NCCN指南的c-statistic为0.55,低于IMPEDE VTE评分。
  • 随着评分升高,VTE风险显著增加(HR 1.20,P<.0001)。

核心结论

  • IMPEDE VTE评分优于现行IMWG/NCCN指南,可考虑作为多发性骨髓瘤VTE新的标准风险分层工具。

研究设计与样本

  • 使用退伍军人事务部中央癌症登记处4446例新诊断多发性骨髓瘤开始化疗的患者,采用时间至事件分析开发VTE风险评分。
  • 使用SEER-Medicare数据库4256例患者进行外部验证。

主要发现

  • IMPEDE VTE评分在开发队列c-statistic为0.66,在外部验证队列c-statistic为0.64。
  • 随着评分升高,VTE风险显著增加(HR 1.20,P<.0001)。
  • IMWG/NCCN指南的c-statistic为0.55。

关键数值与推荐

  • IMPEDE VTE评分组成部分包括:免疫调节剂;体重指数≥25 kg/m2;骨盆、髋部或股骨骨折;促红细胞生成素刺激剂;地塞米松/多柔比星;亚洲种族/族裔;VTE病史;隧道式导管/中心静脉导管;现有血栓预防。

临床怎么用

  • IMPEDE VTE评分可用于多发性骨髓瘤患者VTE风险预测,其区分能力优于IMWG/NCCN指南。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Venous thromboembolism (VTE) is a common cause of morbidity and mortality among patients with multiple myeloma (MM). The International Myeloma Working Group (IMWG) developed guidelines recommending primary thromboprophylaxis, in those identified at high-risk of VTE by the presence of risk factors. The National Comprehensive Cancer Network (NCCN) has adopted these guidelines; however, they lack validation. We sought to develop and validate a risk prediction score for VTE in MM and to evaluate the performance of the current IMWG/NCCN guidelines. Using 4446 patients within the Veterans Administration Central Cancer Registry, we used time-to-event analyses to develop a risk score for VTE in patients with newly diagnosed MM starting chemotherapy. We externally validated the score using the Surveillance, Epidemiology, End Results (SEER)-Medicare database (N = 4256). After identifying independent predictors of VTE, we combined the variables to develop the IMPEDE VTE score (Immunomodulatory agent; Body Mass Index ≥25 kg/m2 ; Pelvic, hip or femur fracture; Erythropoietin stimulating agent; Dexamethasone/Doxorubicin; Asian Ethnicity/Race; VTE history; Tunneled line/central venous catheter; Existing thromboprophylaxis). The score showed satisfactory discrimination in the derivation cohort, c-statistic = 0.66. Risk of VTE significantly increased as score increased (hazard ratio 1.20, P = <.0001). Within the external validation cohort, IMPEDE VTE had a c-statistic of 0.64. For comparison, when evaluating the performance of the IMWG/NCCN guidelines, the c-statistic was 0.55. In summary, the IMPEDE VTE score outperformed the current IMWG/NCCN guidelines and could be considered as the new standard risk stratification for VTE in MM.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Sanfilippo KM, Luo S, Wang TF, et al. Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score. Am J Hematol. 2019. PMID: 31379000. doi:10.1002/ajh.25603

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。